Massachusetts Financial Services Co. MA Has $12.51 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Massachusetts Financial Services Co. MA raised its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 28.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 338,909 shares of the biotechnology company's stock after buying an additional 75,692 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.12% of Exelixis worth $12,513,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EXEL. Coppell Advisory Solutions LLC purchased a new stake in shares of Exelixis during the 4th quarter worth $25,000. Colonial Trust Co SC lifted its position in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 765 shares during the last quarter. Bartlett & CO. Wealth Management LLC purchased a new stake in shares of Exelixis during the 1st quarter worth $37,000. Crowley Wealth Management Inc. purchased a new stake in shares of Exelixis during the 4th quarter worth $50,000. Finally, Hurley Capital LLC acquired a new stake in Exelixis during the 4th quarter worth $68,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

Analyst Ratings Changes

EXEL has been the topic of several research analyst reports. Guggenheim set a $45.00 price target on shares of Exelixis and gave the stock a "buy" rating in a research note on Thursday, May 15th. Stifel Nicolaus lifted their price target on shares of Exelixis from $36.00 to $38.00 and gave the stock a "hold" rating in a research note on Wednesday, May 14th. HC Wainwright lifted their price target on shares of Exelixis from $47.00 to $53.00 and gave the stock a "buy" rating in a research note on Monday, June 30th. Benchmark reiterated a "neutral" rating on shares of Exelixis in a research note on Monday, June 23rd. Finally, Jefferies Financial Group set a $50.00 price objective on shares of Exelixis and gave the company a "buy" rating in a research note on Tuesday, June 24th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $45.28.

Exelixis Stock Performance

Shares of Exelixis stock traded down $0.21 during trading hours on Monday, reaching $44.26. The company's stock had a trading volume of 1,796,166 shares, compared to its average volume of 2,535,032. The company's 50 day simple moving average is $43.17 and its 200 day simple moving average is $38.47. Exelixis, Inc. has a one year low of $22.20 and a one year high of $49.62. The stock has a market cap of $12.07 billion, a P/E ratio of 20.12, a price-to-earnings-growth ratio of 0.89 and a beta of 0.28.

Insider Transactions at Exelixis

In related news, Director Tomas J. Heyman sold 4,544 shares of the stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $44.29, for a total value of $201,253.76. Following the completion of the transaction, the director directly owned 32,470 shares of the company's stock, valued at $1,438,096.30. This represents a 12.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jack L. Wyszomierski sold 7,535 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total transaction of $324,683.15. Following the sale, the director owned 358,882 shares in the company, valued at $15,464,225.38. This trade represents a 2.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 458,113 shares of company stock worth $21,024,817 over the last 90 days. Corporate insiders own 2.85% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.